The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Usability, Validity and Biomarker Discovery for Wearable & Mobile Device Measurements of Neurologic Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06219629
Recruitment Status : Recruiting
First Posted : January 23, 2024
Last Update Posted : April 5, 2024
Sponsor:
Information provided by (Responsible Party):
Koneksa Health

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Disease Progression Study

Condition or disease
Parkinson Disease

Detailed Description:
This is a longitudinal, observational Study to Determine Usability, Analytical and Clinical Validity and Biomarker Discovery for Wearable and Mobile Device Collected Objective Measurement of Disturbed Sleep and Neurologic Disorders. The Disease Progression Study part in Parkinson's Disease has a duration of approximately 12 months.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 70 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Two Part, Observational Basket Study to Determine Usability, Validity and Biomarker Discovery for Mobile EEG, Wearable and Device Collected Objective Measurement of Disturbed Sleep and Neurologic Disorders (LEARNS)
Actual Study Start Date : February 20, 2024
Estimated Primary Completion Date : August 2025
Estimated Study Completion Date : September 2025

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Motor Function as Measured by the Neuroscience Toolkit app-based Assessments [ Time Frame: Baseline Day 1 through Day 365 End of Participation ]
    Gait, balance, upper limb function, pronation/supination, finger tap, postural, kinetic and resting tremor

  2. Motor Function in the Context of Daily Living [ Time Frame: Baseline Day 1 through Day 365 End of Participation ]
    As measured by gait and balance calculated from walk periods detected using wrist-worn device

  3. Speech Measures [ Time Frame: Baseline Day 1 through Day 365 End of Participation ]
    Diadochokinetic rate as measured by the repeated phrase task, monotonicity, search time, and description duration as measured by the Picture Description task, articulation rate, speaking rate, articulatory precision, monotonicity, regulation of voicing and pause rate as measured by the Sentence Reading, and maximum phonation time, pitch instability and harmonic strength as measured by the Sustained Phonation task

  4. Cognitive Measures as measured by Cambridge Cognition assessments via the Koneksa mobile application [ Time Frame: Baseline Day 1 through Day 365 End of Participation ]
    Paired Associates Learning (PAL) test, Pattern Recognition Memory (PRM) test, Reaction Time (RT) test, Spatial Working Memory (SWM) test

  5. Daytime Measurements via Wrist-Worn Device [ Time Frame: Baseline Day 1 through Day 365 End of Participation ]
    Oxygen saturation, heart rate variability, superficial temperature, distance walked, average speed, steps, metabolic equivalent of task

  6. Patient Reported Outcomes [ Time Frame: Baseline Day 1 through Day 365 End of Participation ]
    Patient Global Impression of Change (PGI-C) and Patient Global Impression of Severity (PGI-S)

  7. Participant Diary [ Time Frame: Baseline Day 1 through Day 365 End of Participation ]
    Time in and out of bed, number of daytime naps, use of any medications or supplements taken to promote sleep or wakefulness or treat symptoms of central nervous system (CNS) disorders

  8. Daytime Sleep [ Time Frame: Baseline Day 1 through Day 365 End of Participation ]
    Number of naps and duration of each measured by wrist-worn device, measures from sleep-related electronic patient reported outcomes (ePROs)

  9. Objective Measures of Nighttime Sleep [ Time Frame: Baseline Day 1 through Day 365 End of Participation ]
    Nighttime sleep measured by vital signs, heart rate variability plus actigraphy plus oxygen saturation from wrist-worn device

  10. Usability [ Time Frame: Baseline Day 1 through Day 365 End of Participation ]
    Participant and/or caregiver ease of use and satisfaction for the wrist-worn device and neuroscience toolkit app-based assessments

  11. Other Assessments [ Time Frame: Baseline Day 1 through Day 365 End of Participation ]
    Site clinical care team, participant, and/or caregiver likelihood to recommend the neuroscience toolkit


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with Parkinson's disease I. participants without diagnosed obstructive sleep apnea II. participants with diagnosed obstructive sleep apnea
Criteria

Inclusion Criteria:

  1. All study participants

    1.1 Male or female between 18 years and 85 years of age

    1.2 Body mass index (BMI) 18 - 40 kg/m2

    1.3 Participant is judged to be in adequate health other than Parkinson's Diagnosis per Principal Investigator (PI) assessment

    1.4 Participant or caregiver has demonstrated ability to perform satisfactory in-clinic and remote procedures during the screening period

    1.5 Usual nightly total sleep time > 6 hours

    1.6 Participant demonstrates ability to perform satisfactory in-clinic and mobile data collection and respond to questionnaires during the screening training period

    1.7 Parkinson's disease diagnosis defined as:

    1.7.1 Clinically established Parkinson's Disease (PD)

    1.7.2 H&Y stage 1 and 2

  2. In addition to a PD diagnosis, for participants with obstructive sleep apnea (OSA). OSA is defined as:

2.1 Participant demonstrates ability to perform satisfactory in-clinic and at-home mobile data collection and respond to questionnaires during the screening training period

2.2 Diagnosed with moderate to severe obstructive sleep apnea with an apnea hypopnea index (AHI) >= 15 at time of diagnosis

2.3 Participants diagnosed with obstructive sleep apnea but identified as central or complex over the course of this study will be noted but still included as part of this cohort

2.4 Confirmed moderate-severe sleep apnea diagnosis within the last 10 years

2.5 Participants are still eligible for this study if they are on continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP). Duration and frequency data must be documented.

Exclusion Criteria:

  1. Unable to commit to 12 months of data collection.
  2. Planning to enroll in a clinical trial for disease. modifying therapy that will overlap with the duration of this study.
  3. Patients with Parkinsonism due to drugs(s) and or toxin(s)
  4. Patients with increased risk of falling as > 6 falls in the preceding 12 months.
  5. Urine drug screen positive for opiates, phencyclidine (PCP), cocaine, and amphetamines
  6. Subjects who regularly partake in binge drinking as defined by 4 or more drinks for women or 5 or more drinks for men on an occasion per the investigators assessment.
  7. Current, recent (within the past 6 months), or seeking treatment for a substance-related disorder, excluding medical or recreational marijuana.
  8. Current or recent (within the past 6 months) diagnosis of a moderate or severe substance use disorder (excluding caffeine) according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria. Nicotine use disorder is excluded only if it has an effect on sleep (i.e., a subject who routinely awakens at night to smoke). Medical or recreational marijuana is not included in this exclusion criterion.
  9. Use of any over the counter (OTC) or prescription medications that could affect the evaluation within a time period prior to the Baseline visit corresponding to at least 5 half-lives of the drug(s) or planned use of such drug(s) at some point. Examples of excluded medications include OTC stimulants and methylphenidate, amphetamines, modafinil, armodafinil, sodium oxybate, pemoline, pitolisant, bupropion, and opioids. Medications should be discontinued such that, in the opinion of the investigator, the subject has returned to his/her baseline level of daytime sleepiness at least 7 days prior to the Baseline visit. Medical or recreational non-inhaled marijuana is not included in this exclusion criterion.
  10. Subjects with severe cardiopulmonary, hepatic, renal, or musculoskeletal disease such that Activities of Daily Living (ADLs) are adversely impacted.
  11. Any other medical, psychiatric, or social condition that, in the opinion of the investigator, is likely to unfavorably alter the risk-benefit of subject participation, to interfere with protocol compliance, or to confound safety or efficacy assessments.
  12. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 1 month prior to screening.
  13. Participant has a history of neoplastic disease. Exception (1) participant with an adequately treated basal cell carcinoma or carcinoma in situ of the cervix may participate; (2) participants with other malignancies which have been successfully treated > 5 years prior to screening without evidence of recurrence.
  14. Currently participating in another clinical trial or who participated in a previous clinical trial and received any investigational product treatment within 60 days or within at least 5 half-lives of previous investigational product prior to screening visit.
  15. Participants who are pregnant or breastfeeding.
  16. History of seizures, epilepsy, stroke, multiple sclerosis, or traumatic brain injury.
  17. Intracranial metallic or magnetic devices (e.g., cochlear implant, deep brain stimulator).
  18. Pacemaker or any implanted device
  19. Any history of an experimental therapy (e.g., antisense oligonucleotide, cell transplantation or experimental brain surgery).
  20. Current untreated or unstable depressive disorder or a serious mood disorder requiring hospitalization.
  21. Other primary degenerative dementia or neurodegenerative conditions outside of the specific study arm.
  22. Other infectious, metabolic, or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, other laboratory values etc.).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06219629


Contacts
Layout table for location contacts
Contact: Koneksa Health 551-866-0025 KH007@koneksahealth.com

Locations
Layout table for location information
United States, Florida
Parkinsons Disease And Movement Disorders Center Of Boca Raton Recruiting
Boca Raton, Florida, United States, 33486
Contact: Nicolle Thomas    561-392-1818 ext 2    nthomas@parkinsonscenter.org   
Contact: Karla Arias    561-392-1818 ext 2    karias@parkinsonscenter.org   
Principal Investigator: Stuart H Isaacson, MD         
Accel Research Sites DeLand Recruiting
DeLand, Florida, United States, 32720
Contact: Erica Santoni    386-785-2400 ext 109    erica.santoni@accelclinical.com   
Contact: Tiffany Martinez-Torres    386-785-2400 ext 357    tifany.martinez@accelclinical.com   
Principal Investigator: Bruce Rankin, MD         
Accel Research Sites St Petersburg-Largo Recruiting
Largo, Florida, United States, 33777
Contact: Adrianna Cygler    813-877-8839    acygler@accelclinical.com   
Contact: Gail McDonnell    813-877-8839    gmcdonnell@accelclinical.com   
Principal Investigator: Deborah Burke, MD         
N1 Research LLC Recruiting
Orlando, Florida, United States, 32825
Contact: Carem Acosta    407-916-0304 ext 4030    CAcosta@NeurologyOne.com   
Contact: Victor Lameda    407-916-0304 ext 4080    vlameda@NeurologyOne.com   
Principal Investigator: Ramon Rodriguez, MD         
United States, Michigan
Quest Research Institute Recruiting
Farmington Hills, Michigan, United States, 48334
Contact: Sarah Margott    248-957-8940    sarah.morgott@questri.com   
Contact: Ashley Murphy    248-957-8940    ashley.murphy@questri.com   
Principal Investigator: Peter LeWitt, MD         
Sponsors and Collaborators
Koneksa Health
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Koneksa Health
ClinicalTrials.gov Identifier: NCT06219629    
Other Study ID Numbers: KH007
First Posted: January 23, 2024    Key Record Dates
Last Update Posted: April 5, 2024
Last Verified: March 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All individual participant data that underlie results in a publication
Supporting Materials: Study Protocol
Time Frame: Upon preliminary analysis (if applicable) and end of study.
Access Criteria: Publications will be shared with Clinical Site Investigators and industry professionals.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Nervous System Diseases
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
 Central Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases